A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis
FASE/S DEL ENSAYO
Fase II
PATOLOGÍA
Mielofibrosis Primaria
CENTRO INVESTIGADOR
Hospital Universitario de La Princesa – Servicio de Hematología
INVESTIGADOR PRINCIPAL
Javier Loscertales